Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall
Executive Summary
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.
You may also be interested in...
Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes
Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.
FDA Looks Likely To Split Decision On Mepolizumab Approval
An advisory committee was nearly unanimous that GSK’s clinical program demonstrated efficacy and safety for the IL-5 inhibitor in adult patients with severe asthma, but voted no on approval in patients ages 12-17.
GSK Plays Down Seretide/Advair Generic Launch In U.K., But Pressure Builds
Mylan’s launch in the U.K. of the first generic version of anti-asthma drug Seretide (Advair in the U.S.) has been a long-time coming -- and the copycat version has key differences from the original -- but the event underscores building pressures on GSK’s respiratory franchise.